Question 1

What is Retatrutide + Cagrilintide?

Accepted Answer

Pre-mixed metabolic blend combining retatrutide, an investigational GIP/GLP-1/glucagon triple receptor agonist, with cagrilintide, a long-acting amylin analog, both targeting appetite, satiety and energy balance for weight loss. Neither component is FDA-approved: retatrutide is in Eli Lilly's Phase 3 TRIUMPH program (NDA anticipated late 2026, approval not expected before 2027), and cagrilintide is investigational, studied mainly in Novo Nordisk's CagriSema combination. This specific blend is not an approved product and has no published controlled human efficacy or safety data; any rationale is inferred from the separate development-stage compounds, and combination-specific human data is lacking. Merit Verified tracks independent COA test results for Retatrutide + Cagrilintide from multiple vendors.

Question 2

Which vendors sell Retatrutide + Cagrilintide with independent COA testing?

Accepted Answer

3 vendors in the Merit Verified directory have independent COA evidence on file for Retatrutide + Cagrilintide — 5 COAs total. COA coverage and test dates are listed on the Retatrutide + Cagrilintide page at https://meritverified.org/peptides/retatrutide-cagrilintide.

Question 3

How do I verify the quality of Retatrutide + Cagrilintide from a vendor?

Accepted Answer

To verify Retatrutide + Cagrilintide quality, look for an independent certificate of analysis (COA) from a third-party lab — not a lab the vendor owns or pays directly. The COA should state the tested compound, lot number, purity percentage (identity and concentration), and the lab's name. Cross-reference the lot number against the vendor's current stock. Merit Verified indexes COAs for Retatrutide + Cagrilintide at https://meritverified.org/peptides/retatrutide-cagrilintide so you can compare evidence across vendors before buying.

Question 4

What is the regulatory status of Retatrutide + Cagrilintide?

Accepted Answer

Retatrutide + Cagrilintide is classified as research-use only in the Merit Verified registry. In the United States, the FDA removed several peptides including BPC-157, TB-500, and GLP-1 analogues from the 503A compounding ingredient list in April 2026, restricting their use in compounded drugs for human administration. Vendors selling Retatrutide + Cagrilintide for research purposes are not selling it as a drug or supplement; the legal status of purchasing for personal use varies by jurisdiction. Merit Verified does not provide legal or medical advice — confirm current regulatory status with a licensed professional.

Retatrutide + Cagrilintide

Pricing for Retatrutide + Cagrilintide

COAs for Retatrutide + Cagrilintide

5 citations indexed for Retatrutide + Cagrilintide

Beyond weight loss: multisystem benefits of obesity medications

Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review

The Endocannabinoid System in the Development and Treatment of Obesity: Searching for New Ideas

Advancements in the management of obesity: a review of current evidence and emerging therapies

The weight reduction mediated by anti-obesity medication and the cardiovascular outcome